Brind.
  1. Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.

Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.

32 reports, 10 independent Updated Sep 16
Gone quiet Reached 15 outlets in its first 24 hours
Reports
32
Developments
5
Repetition
94%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 10 independent outlets

Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.

Who's involved

What this event is mainly about
AstraZenecaBristol-Myers Squibb

How it developed

Newest first. Tap a step to see who reported it.
  1. Bristol-Myers Squibb and AstraZeneca announced a collaboration on advanced cancer drug development.Sub-event
  2. Market reacted negatively to developments in the merger talks between BMS and AstraZeneca.1 source
  3. AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.Sub-event
  4. Potential merger discussions involving major pharmaceutical companies like Eli Lilly, AstraZeneca, and AbbVie are underway.Sub-event
  5. Ongoing deal talks between AstraZeneca and BMS could lead to a major pharmaceutical merger.1 source

Keep exploring

Part of

Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
22 more outlets ran the same wire story